Please login to the form below
Deal Watch table for July 2013
Table listing all the major pharma mergers, acquisitions and collaborations in the past month
This table lists all the major pharma collaborations, acquisitions and mergers agreed during July 2013.
For an indepth analysis of these deals, read 'Pharma deals during July 2013'
|
Licensor acquired / licensee acquirer |
Deal type |
Product / technology |
Headline ($m) |
| Elan / Perrigo | Acquisition | Tysabri royalty stream, R&D programmes/ EU HQ & operations | 8,600 |
| Trius Therapeutics / Cubist Pharmaceuticals | Acquisition | Antibiotic pipeline inc TR-701 (tedizolid phosphate, p3) | 818 |
| *FibroGen / AstraZeneca | Strategic collaboration | FG-4592, oral treatment for anaemia in renal disease (p2/3) | 815 |
| Optimer Pharmaceuticals / Cubist Pharmaceuticals | Acquisition | Antibiotic pipeline based on Dificid (fidaxomicin) for C.difficile (approved) | 801 |
| Bever Pharmaceutical / Pharmstandard | Acquisition | Singapore-based pharma business | 630 |
| Immunocore / GSK | Research collaboration and licence | ImmTacs discovery platform against multiple targets | 510 |
| Quest Diagnostics / Royalty Pharma | Purchase of royalty rights | Ibrutinib (Bruton's tyrosine kinase inhibitor) for CLL and other B-cell cancers (p3) | 485 |
| Array BioPharma / Loxo Oncology | Multi-year licence and collaboration | Drug candidate (preclinical)+ discovery of small molecule drugs for oncology targets | 434 |
| Array BioPharma / Celgene | Collaboration and option | Programme targeting novel inflammation pathway (preclinical) | 387 |
| Ceptaris Therapeutics / Actelion | Acquisition | Valchlor for mycosis fungoides-type CTCL (NDA) | 250 |
| Syntaxin / Ipsen | Acquisition of 90% stake | Serenbotase (p2) and other recombinant botulinum toxins | 210 |
| Medicago / Mitsubishi Tanabe Pharma | Acquisition of 60% stake | Portfolio of flu and other vaccines based on VLPs (p2) | 208 |
| Talon Therapeutics / Spectrum Pharmaceuticals | Acquisition | Haemato-oncology portfolio, Marqibo for leukaemia (FDA approved) | 206 + shares |
| Bionomics / Merck & Co | Option and licence | ionX drug discovery and MultiCore chemistry platform (discovery) | 172 |
| Nerviano Medical Sciences / Servier | Collaboration, licence, option | Protein kinase TTK/MPS1 inhibitors (preclinical) | 143 |
| Lilly / Transition Therapeutics | Licence, collaboration and option*‡ | TT-601 for osteoarthritis pain (preclinical) | 130*‡ |
| **Vivus / Berlin-Chemie (Menarini) | Licence, commercialisation, supply | Spedra (avanafil) for erectile dysfunction (approved) | 121 |
| ‡Optinose / Avanir Pharmaceuticals | Licence | Breath Powered intranasal sumatriptan for migraine (p3) | 110 |
| Acetylon Pharmaceuticals / Celgene | Collaboration and option to acquire | HDAC inhibitors inc ACY-1215 for multiple myeloma (p1b) | 100 |
| ‡‡Servier / Amgen | Cardiovascular collaboration, licence and option | Procoralan (ivabradine, approved), S38844 (p2), omecamtiv mecarbil (p2) | 50 |
| Opalia Pharma / Recordati | Acquisition of 90% stake | Branded generic drugs - dermatology, GI, respiratory | 49 |
| †Auxilium Pharmaceuticals/ Swedish Orphan Biovitrum | Development, supply and commercialisation | Xiapex (collagenase clostridium histolyticum) (approved) | 40 |
All deals are worldwide unless otherwise noted – see below:
* US, China and all major markets ex Japan, Europe, CIS, Middle East, South Africa
** Over 40 European countries, Australia, New Zealand
‡ North America
‡‡ Amgen receives US rights to Servier's ivabradine and an exclusive option to Servier's S-38844 in the US; Servier receives rights in Europe for omecamtiv mecarbil
† EU
*‡ Payable to Transition Therapeutics if Lilly exercises its option to re-acquire at clinical proof of concept
Abbreviations
ImmTacs = Immune mobilising mTCR against cancer
CLL = chronic lymphocytic leukaemia
CTCL = cutaneous T-cell lymphoma
VLP = virus-like particle produced in plant expression systems
Subscribe to our email news alerts
- Senior Medical Copywriter - Highly Awarded Advertising Agency
- £50,000 - £60,000 yearly
- Market Access Director, six figure base salary and £5K joining b...
- Highly competitive salary
- Account Manager, Healthcare Marketing Creative Agency, Fixed ter...
- Highly competitive salary
- Home Based Account Manager, Medical Communications, UK, Pharma/M...
- Highly competitive salary
- Account Director, Healthcare Marketing Creative Agency, Fixed te...
- Highly competitive salary
- Account Manager, 6 month contract, Healthcare Brand communicatio...
- Highly competitive salary
- Novartis receives EC approval for Cosentyx in hidradenitis suppurativa
- BMS and Janssen’s antithrombotic granted FDA fast track designation
- Sanofi's frexalimab shows promise in relapsing forms of MS
- EMA recommends revoking marketing authorisation for Novartis’ sickle cell disease drug
- Pfizer’s antibiotic combination shows promise in treating multi-drug resistant infections
- Amgen reports positive results for Otezla in psoriatic arthritis
- Medscape Education is Focusing on Patient Centricity and Education Outcomes at EHA 2023
- Pfizer reports positive results for elranatamab in multiple myeloma
- Amgen’s Lumakras shows promise in phase 3 lung cancer study
- Adaptive innovation
- Archetypes: Rethinking go-to-market expectations to drive commercial success
- Navigating patients step by step on their clinical trial journey
No results were found
PMHub
Genetic Digital
Genetic Digital specialises in developing digital marketing solutions for the healthcare, medical and pharmaceutical sectors. From developing a digital strategy,...
